• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

拓展靶向分子动力学的能力:纤溶酶原激活物抑制剂1中大构象转变的模拟

Extending the capabilities of targeted molecular dynamics: simulation of a large conformational transition in plasminogen activator inhibitor 1.

作者信息

Krüger P, Verheyden S, Declerck P J, Engelborghs Y

机构信息

Laboratory of Biomolecular Dynamics, Katholieke Universiteit Leuven, 3001 Leuven, Belgium.

出版信息

Protein Sci. 2001 Apr;10(4):798-808. doi: 10.1110/ps.40401.

DOI:10.1110/ps.40401
PMID:11274471
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2373958/
Abstract

Plasminogen activator inhibitor type 1 (PAI-1) is an inhibitor of plasminogen activators such as tissue-type plasminogen activator or urokinase-type plasminogen activator. For this molecule, different conformations are known. The inhibiting form that interacts with the proteinases is called the active form. The noninhibitory, noncleavable form is called the latent form. X-ray and modeling studies have revealed a large change in position of the reactive center loop (RCL), responsible for the interaction with the proteinases, that is inserted into a beta-sheet (s4A) in the latent form. The mechanism underlying this spontaneous conformational change (half-life = 2 h at 37 degrees C) is not known in detail. This investigation attempts to predict a transition path from the active to the latent structure at the atomic level, by using simulation techniques. Together with targeted molecular dynamics (TMD), a plausible assumption on a rigid body movement of the RCL was applied to define an initial guess for an intermediate. Different pathways were simulated, from the active to the intermediate, from the intermediate to the latent structure and vice versa under different conditions. Equilibrium simulations at different steps of the path also were performed. The results show that a continuous pathway from the active to the latent structure can be modeled. This study also shows that this approach may be applied in general to model large conformational changes in any kind of protein for which the initial and final three-dimensional structure is known.

摘要

纤溶酶原激活物抑制剂1型(PAI-1)是组织型纤溶酶原激活物或尿激酶型纤溶酶原激活物等纤溶酶原激活物的抑制剂。对于这种分子,已知有不同的构象。与蛋白酶相互作用的抑制形式称为活性形式。非抑制性、不可裂解的形式称为潜伏形式。X射线和建模研究表明,负责与蛋白酶相互作用的反应中心环(RCL)的位置发生了很大变化,在潜伏形式中它插入到一个β折叠(s4A)中。这种自发构象变化(37℃下半衰期 = 2小时)的潜在机制尚不清楚。本研究试图通过使用模拟技术在原子水平预测从活性结构到潜伏结构的转变路径。结合靶向分子动力学(TMD),对RCL的刚体运动应用了一个合理假设来定义中间体的初始猜测。在不同条件下模拟了从活性结构到中间体、从中间体到潜伏结构以及反之亦然的不同路径。还对路径不同步骤进行了平衡模拟。结果表明,可以构建从活性结构到潜伏结构的连续路径。这项研究还表明,这种方法通常可应用于为已知初始和最终三维结构的任何类型蛋白质的大构象变化建模。

相似文献

1
Extending the capabilities of targeted molecular dynamics: simulation of a large conformational transition in plasminogen activator inhibitor 1.拓展靶向分子动力学的能力:纤溶酶原激活物抑制剂1中大构象转变的模拟
Protein Sci. 2001 Apr;10(4):798-808. doi: 10.1110/ps.40401.
2
A model of the reactive form of plasminogen activator inhibitor-1.纤溶酶原激活物抑制剂-1反应形式的模型。
J Struct Biol. 1994 Nov-Dec;113(3):239-45. doi: 10.1006/jsbi.1994.1058.
3
Protein conformational change delayed by steric hindrance from an N-linked glycan.N-连接聚糖的空间位阻延迟蛋白质构象变化。
J Mol Biol. 2013 Aug 23;425(16):2867-77. doi: 10.1016/j.jmb.2013.05.007. Epub 2013 May 20.
4
A peptide mimicking the C-terminal part of the reactive center loop induces the transition to the latent form of plasminogen activator inhibitor type-1.一段模拟反应中心环 C 末端部分的肽诱导纤溶酶原激活物抑制剂-1 向潜伏形式的转变。
FEBS Lett. 2012 Mar 23;586(6):686-92. doi: 10.1016/j.febslet.2012.02.013. Epub 2012 Feb 17.
5
Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.1型纤溶酶原激活物抑制剂——通过蛋白水解敏感性探究潜伏型、活性型、反应中心裂解型和与纤溶酶原激活物复合型之间的构象差异。
Eur J Biochem. 1997 Sep 15;248(3):775-85. doi: 10.1111/j.1432-1033.1997.t01-1-00775.x.
6
Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.反应中心环和β链5A的构象变化伴随纤溶酶原激活物抑制剂1的温度依赖性抑制剂-底物转变。
Eur J Biochem. 1996 Oct 1;241(1):38-46. doi: 10.1111/j.1432-1033.1996.0038t.x.
7
RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1.RNA 适体作为纤维蛋白溶酶原激活物抑制剂-1 的构象探针和调节因子。
Biochemistry. 2010 May 18;49(19):4103-15. doi: 10.1021/bi100066j.
8
Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1.L-抗凝血酶的制备性诱导与表征:潜在纤溶酶原激活物抑制剂-1的结构同源物
Biochemistry. 1997 Oct 21;36(42):13133-42. doi: 10.1021/bi970664u.
9
Rational design of complex formation between plasminogen activator inhibitor-1 and its target proteinases.纤溶酶原激活物抑制剂-1与其靶蛋白酶之间复合物形成的合理设计。
J Struct Biol. 1997 Apr;118(3):236-42. doi: 10.1006/jsbi.1997.3860.
10
Plasminogen activator inhibitor-1 is locked in active conformation and polymerizes upon binding ligands neutralizing its activity.纤溶酶原激活物抑制剂-1处于活性构象并在结合配体时聚合,从而中和其活性。
Int J Mol Med. 2006 Mar;17(3):437-47.

引用本文的文献

1
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.心血管疾病中靶向纤溶酶原激活物抑制剂-1:纤溶酶原激活物抑制剂-1功能及抑制作用的结构见解
Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. eCollection 2020.
2
Conformational preludes to the latency transition in PAI-1 as determined by atomistic computer simulations and hydrogen/deuterium-exchange mass spectrometry.原子模拟计算和氘代/氢交换质谱法测定的 PAI-1 潜伏态转变的构象前序。
Sci Rep. 2017 Jul 26;7(1):6636. doi: 10.1038/s41598-017-06290-0.
3
Building a More Predictive Protein Force Field: A Systematic and Reproducible Route to AMBER-FB15.构建更具预测性的蛋白质力场:通往AMBER-FB15的系统且可重复的途径。
J Phys Chem B. 2017 Apr 27;121(16):4023-4039. doi: 10.1021/acs.jpcb.7b02320. Epub 2017 Apr 6.
4
Principles and Overview of Sampling Methods for Modeling Macromolecular Structure and Dynamics.用于大分子结构与动力学建模的采样方法原理与概述
PLoS Comput Biol. 2016 Apr 28;12(4):e1004619. doi: 10.1371/journal.pcbi.1004619. eCollection 2016 Apr.
5
Striking HIV-1 Entry by Targeting HIV-1 gp41. But, Where Should We Target?通过靶向HIV-1 gp41来显著抑制HIV-1进入。但是,我们应该靶向哪里呢?
PLoS One. 2016 Jan 19;11(1):e0146743. doi: 10.1371/journal.pone.0146743. eCollection 2016.
6
Molecular dynamics simulations: advances and applications.分子动力学模拟:进展与应用
Adv Appl Bioinform Chem. 2015 Nov 19;8:37-47. doi: 10.2147/AABC.S70333. eCollection 2015.
7
Serpin latency transition at atomic resolution.丝氨酸蛋白酶抑制剂在原子分辨率下的潜伏态转变。
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15414-9. doi: 10.1073/pnas.1407528111. Epub 2014 Oct 13.
8
Elucidating the ensemble of functionally-relevant transitions in protein systems with a robotics-inspired method.用一种受机器人技术启发的方法阐明蛋白质系统中功能相关转变的整体情况。
BMC Struct Biol. 2013;13 Suppl 1(Suppl 1):S8. doi: 10.1186/1472-6807-13-S1-S8. Epub 2013 Nov 8.
9
Exploration of the activation pathway of Deltaalpha-Chymotrypsin with molecular dynamics simulations and correlation with kinetic experiments.通过分子动力学模拟探索δ-α-糜蛋白酶的激活途径及其与动力学实验的相关性。
Eur Biophys J. 2008 Nov;38(1):13-23. doi: 10.1007/s00249-008-0348-2. Epub 2008 Aug 27.
10
Molecular dynamics: survey of methods for simulating the activity of proteins.分子动力学:蛋白质活性模拟方法综述
Chem Rev. 2006 May;106(5):1589-615. doi: 10.1021/cr040426m.

本文引用的文献

1
Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1.
Thromb Haemost. 2000 Nov;84(5):871-5.
2
Structure of a serpin-protease complex shows inhibition by deformation.丝氨酸蛋白酶抑制剂-蛋白酶复合物的结构显示通过变形实现抑制作用。
Nature. 2000 Oct 19;407(6806):923-6. doi: 10.1038/35038119.
3
The structure of a serpin-protease complex revealed by intramolecular distance measurements using donor-donor energy migration and mapping of interaction sites.通过使用供体-供体能量迁移的分子内距离测量和相互作用位点映射揭示的丝氨酸蛋白酶抑制剂-蛋白酶复合物的结构。
Structure. 2000 Apr 15;8(4):397-405. doi: 10.1016/s0969-2126(00)00121-0.
4
Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.纤溶酶原激活物抑制剂1。天然丝氨酸蛋白酶抑制剂的结构,与其他构象的比较及其对丝氨酸蛋白酶抑制剂失活的影响。
J Mol Biol. 2000 Mar 31;297(3):683-95. doi: 10.1006/jmbi.2000.3604.
5
Conformational changes in serpins: I. The native and cleaved conformations of alpha(1)-antitrypsin.丝氨酸蛋白酶抑制剂的构象变化:I. α1-抗胰蛋白酶的天然构象和裂解构象。
J Mol Biol. 2000 Jan 21;295(3):651-65. doi: 10.1006/jmbi.1999.3375.
6
Predictive value of fibrinolytic factors in coronary heart disease.纤溶因子在冠心病中的预测价值。
Scand J Clin Lab Invest Suppl. 1999;230:23-31.
7
The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion.纤溶酶原激活物抑制剂1的活性构象,一种控制纤维蛋白溶解和细胞黏附的药物靶点。
Structure. 1999 Feb 15;7(2):111-8. doi: 10.1016/S0969-2126(99)80018-5.
8
Simulations of the T <--> R conformational transition in aspartate transcarbamylase.
Protein Eng. 1999 Apr;12(4):285-95. doi: 10.1093/protein/12.4.285.
9
Systematic analysis of domain motions in proteins from conformational change: new results on citrate synthase and T4 lysozyme.从构象变化角度对蛋白质结构域运动进行系统分析:柠檬酸合酶和T4溶菌酶的新结果
Proteins. 1998 Feb 1;30(2):144-54.
10
Modelling pathways of alpha-chymotrypsin activation and deactivation.模拟α-胰凝乳蛋白酶激活与失活的途径。
Protein Eng. 1997 Oct;10(10):1163-74. doi: 10.1093/protein/10.10.1163.